| 24/04/2025 | 盧安邦 | 1312(S) | -1,707,700(S) | | 5,000,000(L) | 4.39 | | 21/03/2025 | Vivo Plenilune IX Limited | 1711(L) | 37,167,064(L) | | 37,167,064(L) | 32.62 | | 21/03/2025 | Vivo Plenilune IX Limited | 1001(L) | 36,136,364(L) | | 36,136,364(L) | 32.14 | | 21/03/2025 | Vivo Capital Fund IX(Cayman), L.P. | 1001(L) | 36,136,364(L) | | 36,136,364(L) | 32.14 | | 21/03/2025 | Ascendis Pharma Endocrinology Division A/S | 1701(L) | | | 20,568,182(L) | 18.05 | | 21/03/2025 | Ascendis Pharma Bone Diseases A/S | 1701(L) | | | 12,855,114(L) | 11.28 | | 21/03/2025 | Ascendis Pharma A/S | 1701(L) | | | 41,136,364(L) | 36.11 | | 21/03/2025 | 盧安邦 | 1701(L)
1313(S) | +5,000,000(L)
+1,707,700(S) | | 5,000,000(L)
1,707,700(S) | 4.39
1.49 | | 21/03/2025 | Ascendis Pharma Growth Disorders A/S | 1701(L) | | | 7,713,068(L) | 6.77 | | 21/03/2025 | Vivo Capital IX (Cayman), LLC | 1001(L) | 36,136,364(L) | | 36,136,364(L) | 32.14 | | 21/03/2025 | Vivo Capital Fund IX(Cayman), L.P. | 1711(L) | 37,167,064(L) | | 37,167,064(L) | 32.62 | | 21/03/2025 | Vivo Capital IX (Cayman), LLC | 1711(L) | 37,167,064(L) | | 37,167,064(L) | 32.62 | | | 1 |
|
